Trials / Terminated
TerminatedNCT00706797
Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel™ (Etanercept) Added to Methotrexate in Comparison With Usual Treatment in Subjects With Moderate Rheumatoid Arthritis Disease Activity
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 141 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess comparative radiographic efficacy, clinical efficacy and safety of etanercept (ETN) + methotrexate (MTX) with usual disease-modifying anti-rheumatic drug (DMARD) treatment in subjects with moderate RA who were treated with MTX monotherapy, but continue to have moderate disease activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | etanercept (EnbrelTM) | |
| DRUG | methotrexate |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-12-01
- Completion
- 2010-05-01
- First posted
- 2008-06-30
- Last updated
- 2011-06-21
- Results posted
- 2011-01-10
Locations
45 sites across 9 countries: Czechia, France, Germany, Hungary, Italy, Poland, Spain, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00706797. Inclusion in this directory is not an endorsement.